US Stock MarketDetailed Quotes
RENB Renovaro
- 0.551
- +0.041+8.04%
Close Oct 14 16:00 ET
- 0.558
- +0.007+1.31%
Post 17:39 ET
86.06MMarket Cap-655P/E (TTM)
0.590High0.481Low227.65KVolume0.529Open0.510Pre Close124.83KTurnover0.25%Turnover RatioLossP/E (Static)156.19MShares5.25052wk High0.65P/B49.88MFloat Cap0.39552wk Low--Dividend TTM90.53MShs Float13.780Historical High--Div YieldTTM21.33%Amplitude0.393Historical Low0.548Avg Price1Lot Size
About Renovaro Company
Renovaro, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. The company was founded by Rene Sindlev and Serhat Gumrukcu on January 18, 2011 and is headquartered in Los Angeles, CA.
Company Profile
SymbolRENB
Company NameRenovaro
Listing DateDec 10, 2018
Founded2011
CEODr. Mark R. Dybul, M.D.
MarketNASDAQ
Employees25
Fiscal Year Ends06-30
Address1927 Paseo Rancho Castillo
CityLos Angeles
ProvinceCalifornia
CountryUnited States of America
Zip Code90032-2012
Phone1-305-918-1980
Websitehttp://renovarobio.com
Company Executives
- Name
- Position
- Salary
- Dr. Mark R. Dybul, M.D.
- Executive Vice Chairman of the Board and Chief Executive Officer
- 1.41M
- Simon Tarsh
- Interim Chief Financial Officer and Principal Accounting Officer
- --
- Rene Sindlev
- Chairman of the Board
- 153.71K
- Francois Binette
- Managing Director and President
- 881.57K
- Avram Miller
- Director
- --
- Karen Brink
- Director
- --
- James Sapirstein
- Independent Director
- 133.62K
- Gregg H. Alton, J.D.
- Independent Director
- 133.21K
- Ruud Hendriks
- Independent Director
- --
- Dr. Carol L. Brosgart, M.D.
- Independent Director
- 124.71K
- Jayne McNicol
- Independent Director
- 131.25K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
